This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ductal carcinoma in situ
Surg Clin North Am. 2013 Apr;93(2) :393-410
AbstractManagement of ductal carcinoma in situ (DCIS) has evolved from radical surgery to the option of a more minimally invasive approach. Data show that breast conservation surgery performed with administration of radiotherapy, like mastectomy, is feasible and safe. Because efforts to find a safe group for elimination of radiotherapy have resulted in data that conflict, radiotherapy still remains standard of care as a part of breast conservation for DCIS. Tamoxifen has also shown a significant recurrence benefit and has become standard in the treatment of receptor-positive disease. Investigation of other agents, such as anastrazole and trastuzumab, are ongoing.
NotesBleicher, Richard J United States The Surgical clinics of North America Surg Clin North Am. 2013 Apr;93(2):393-410. doi: 10.1016/j.suc.2012.12.001. Epub 2013 Jan 29.